High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

Area of Science:

• Hepatology and Gastroenterology
• Clinical Trial Research
• Drug Efficacy Studies

Background:

• Primary sclerosing cholangitis (PSC) lacks effective medical treatments.
• Ursodeoxycholic acid (UDCA) is used, but optimal dosing for PSC is debated.
• Higher UDCA doses have been explored for potential benefits in PSC.

Purpose of the Study:

• To evaluate the effect of a higher dose of ursodeoxycholic acid (UDCA) compared to placebo.
• To assess UDCA's impact on survival, symptoms, biochemistry, and quality of life in PSC patients.
• To determine if increased UDCA dosage offers a survival benefit in primary sclerosing cholangitis.

Main Methods:

• A 5-year randomized, placebo-controlled trial involving 219 PSC patients.
• Patients received either 17-23 mg/kg/day of UDCA or a placebo.
• Quality of life assessed using the Medical Outcomes Study 36-item Short-Form Health Survey.

Main Results:

• No statistically significant difference in the combined endpoint of death or liver transplantation between UDCA and placebo groups (7.2% vs 10.9%).
• A trend towards reduced liver transplantation in the UDCA group was not statistically significant.
• No significant differences observed in symptom burden or quality of life between the groups.

Conclusions:

• High-dose ursodeoxycholic acid (UDCA) did not demonstrate a statistically significant benefit for survival in primary sclerosing cholangitis (PSC).
• The study found no evidence that higher UDCA doses prevent cholangiocarcinoma in PSC patients.
• Further research may be needed to explore alternative therapeutic strategies for PSC.